Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.” ...
The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...
investigators and study staff for their participation in our clinical trials,” co-founder and CEO Anne Wojcicki said in a ...
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our ...